Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases
NCT ID: NCT03189576
Last Updated: 2023-05-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
37 participants
INTERVENTIONAL
2015-10-01
2023-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We will show that the assessment of ctDNA is a non-invasive approach and easily taken at different time points via simple blood draw to monitor residual disease from the colorectal cancer patients after primary surgery. Minimal residual disease could be used in the future for individualized treatment decisions after primary surgery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feasibility of Circulating Tumour DNA (ctDNA) Analysis Using Automated Capillary Blood Sampling
NCT07310537
Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases
NCT06404593
Circulating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion
NCT02579278
GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing CtDNA Diagnostics - Colorectal Cancer
NCT06111105
ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases
NCT05787197
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CRC patients after primary surgery
sequential blood draw taken to monitor residual disease
blood draw
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood draw
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tampere University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pirkko-Liisa Kellokumpu-Lehtinen
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pirkko-Liisa Kellokumpu-Lehtinen, professor
Role: STUDY_DIRECTOR
Tampere University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tampere University Hospital
Tampere, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ETL R15085
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.